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Current therapy in HAM/TSP includes antiretrovirals
and immunomodulators, such as corticosteroids and
interferons, with modest clinical benefit. Since there
are no validated biomarkers to monitor disease severity
(DS), progression or prognosis, we investigated the ex
vivo expression of CD80 and CD86 as possible biomar-
kers, as well as the effect of IFN-a/beta on their in
vitro expression in 16 Brazilian HAM/TSP patients
and 15 healthy controls (HC). Flow cytometry quantifi-
cation indicated significantly elevated expression of
both CD80 and CD86 ex vivo in T (p=0.044 and
p=0.0016) and B (p=0.0003 and p=0.0057) cells, as
compared to HC. In B cells, the ex vivo percentage of
CD80+ positively correlated to DS (p=0.0083, r=0.78),
but not age or disease duration, while ex vivo expres-
sion of CD80 was gender-biased, being significantly
h i g h e ri nw o m e n( p = 0 . 0 2 8 ) .U p o ni nv i t r oc u l t u r e ,
CD80+ (p=0.037) and CD86+ lymphocytes significantly
expand (p<0.0001), as compared to ex vivo levels, in
patients only. In vitro treatment of patients’ PBMCs
with IFN-beta, but not IFN-a resulted in significant
stimulation of B cell CD86 expression (p<0.05). In HC,
both IFN-a and IFN-beta brought about a significant
increase in CD86 expression (p<0.05 and p<0.001).
Neither IFN-a nor IFN-beta was able to significantly
induce B cell CD80 expression in HC or patients. Con-
sequently, B cell CD86/CD80 ratio was significantly
increased upon stimulationw i t hI F N - b e t ai nb o t hH C
and patients. In conclusion, we propose novel biomar-
kers for possible clinical use in HAM/TSP trials: ex
vivo CD80+ B cells positively correlating to DS and
CD86+ B cells preferentially induced by IFN-beta.
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